Integra Dermal Substitute Closes Refractory Bullous Pemphigoid Ulcer After Year of Standard Care

A skin ulcer that resisted a full year of guideline-based bullous pemphigoid treatment healed within four months after surgeons covered it with a bovine-collagen dermal substitute rather than a skin graft, Cureus reported this week.

The case, published in Cureus, involves a 57-year-old man whose lower-leg wounds kept breaking down despite corticosteroids, mycophenolate, doxycycline and compression dressings. Most bullous pemphigoid patients respond to medication alone.

Bullous pemphigoid is largely a disease of people over 70, with European studies citing an annual incidence of 2.4 to 23 new cases per million people, and the European Academy of Dermatology and Venereology (EADV) considers corticosteroids combined with wound care the mainstay of treatment. When that mainstay fails, Cureus noted, published guidance on what to do next is thin.

The surgical team’s reasoning was specific to the disease itself. Bullous pemphigoid attacks the dermoepidermal junction — the anchor zone where the epidermis grips the dermis — and surgery or skin-graft donor sites can themselves trigger flares.

Taking skin from one place to patch another risks creating a new blistering wound. The team instead used Integra Bilayer Matrix Wound Dressing, a sheet of bovine tendon collagen and chondroitin-6-sulfate glycosaminoglycans under a semipermeable silicone layer, secured with sutures and sealed under negative pressure wound therapy.

Artificial collagen scaffold enables skin regrowth without donor graft

  • Bullous pemphigoid is an autoimmune blistering disease in which the body’s own antibodies attack the “anchors” holding skin layers together, causing tense blisters and intense itching.
  • Most patients improve with steroid creams or tablets, but a minority develop ulcers that never close under standard care.
  • In this one case, an artificial collagen “scaffold” let the patient’s own skin cells regrow over the wound without harvesting a donor graft — which can provoke new blisters in this disease.

A year of dressings, then surgery

The patient’s diagnosis rested on classic findings: a biopsy showing linear IgM in a U-serrated pattern, C3 deposition along the basement membrane zone, and a positive ELISA for BP180 antibodies — a test the literature review in Cureus puts at 85% sensitivity and 98% specificity for the NC16A domain of the BP180 protein.

For roughly a year, outpatient dermatology tried the full conservative arsenal: Unna boot compression with triamcinolone, oral prednisone, mycophenolate, doxycycline, weekly dressing changes with Vaseline, collagenase ointment to debride slough, and a three-layer compression wrap from toes to knee.

The ulcers persisted. Heel osteomyelitis followed, forcing multidisciplinary surgery: orthopedic surgeons debrided and washed out the heel, plastic surgeons covered it with an anterolateral thigh free flap, and the 4×3 cm anterior shin wound — with no exposed bone — got sharp debridement plus the dermal substitute.

At four-month follow-up, both wounds showed re-epithelialization with no recurrent ulceration, no infection and no bullous pemphigoid flare, Cureus reported. The patient had been tapered off prednisone six months before surgery.

Why the scaffold worked where grafts were risky

Dermal substitutes act as an acellular scaffold — a temporary framework that lets blood vessels grow in and new dermal tissue form. They are established tools in burn reconstruction; their use in refractory bullous pemphigoid wounds is what this case adds to the record.

Negative pressure wound therapy did double duty here: it pressed the substitute onto the wound bed and, per the report, promoted cell migration and new vessel growth through the collagen matrix.

The disease mechanism explains the caution. Immunoglobulin G attacks the hemidesmosomal proteins BP180 (type XVII collagen) and BP230, activating complement C3 and an eosinophil-driven inflammatory cascade that releases metalloproteinase 9, neutrophil elastase and reactive oxygen species — shredding the very anchors a skin graft would depend on.

Feature What the sources report
Annual incidence 2.4–23 new cases per million (European studies)
Typical age Over 70 years
BP180 ELISA performance 85% sensitivity, 98% specificity
Head/neck/mucosal sparing 80%–90% of cases
Shin wound healed 4×3 cm, closed at four months

What standard care looks like before surgery

Per the EADV guidance cited in the report, treatment is severity-based. Superpotent topical corticosteroids such as clobetasol come first for localized disease; oral prednisone serves moderate-to-severe cases, tapered over months once new blisters stop forming.

Second-line immunosuppressants — methotrexate, mycophenolate mofetil, azathioprine — spare patients long-term steroid exposure. Nonimmunosuppressive options include doxycycline plus nicotinamide, dapsone and dupilumab; refractory disease may justify rituximab, omalizumab or intravenous immune globulin.

Long-term steroids carry their own wound-healing penalty: they inhibit fibroblast collagen synthesis, thin the skin and raise infection risk — a direct conflict for a patient whose problem is a nonhealing wound. The report notes oral vitamin A can partially reverse the collagen-synthesis effect.

Where patients can access this

Dermal substitutes are regulated medical devices on both sides of the Atlantic, used routinely in burn centers in the United States and Europe. Access for a bullous pemphigoid wound, however, depends on a multidisciplinary team — dermatology, orthopedic surgery and plastic surgery working together, as this patient’s care did. No clinical trial yet establishes this approach at population scale; the evidence base remains a single documented case.

On funding: no funding source or manufacturer involvement is declared in the Cureus case report, and no industry-sponsored trial of dermal substitutes in bullous pemphigoid is cited in its literature review.

Skin grafting can trigger bullous pemphigoid flares at donor sites

  • This approach was chosen precisely because skin grafting can precipitate bullous pemphigoid flares at donor sites; patients with active or recently controlled disease should discuss that risk before any grafting procedure.
  • Any nonhealing ulcer on immunosuppressive therapy warrants prompt medical review; signs of spreading infection or bone pain need urgent evaluation.
  • Drug-induced bullous pemphigoid has been linked to NSAIDs, amoxicillin, checkpoint inhibitors, gliptins, TNF-alpha inhibitors, spironolactone and furosemide; medication review belongs in the workup.

One patient, no trials yet

The report’s own conclusion is candid: chronic wounds in bullous pemphigoid are complex, and literature on surgical management of these ulcers is limited. A four-month healed shin in a single patient is a signal, not a standard.

What remains unknown is whether dermal substitutes would outperform conservative wound care in refractory cases across a whole population — a question no published trial has yet answered.

References

  • Cureus — “Refractory Bullous Pemphigoid Ulcer Successfully Treated With Dermal Substitute: A Case Report”
  • European Academy of Dermatology and Venereology (EADV) guidance on bullous pemphigoid management, as cited in the case report
  • Peer-reviewed literature on bullous pemphigoid epidemiology, diagnosis and direct immunofluorescence standards, as cited in the Cureus literature review (Lever, 1953, and subsequent immunopathology studies)
  • Peer-reviewed literature on dermal matrix wound reconstruction and negative pressure wound therapy, as cited in the Cureus discussion

Medical disclaimer: This article is informational reporting on a published case report and does not constitute medical advice. Treatment decisions belong with a qualified clinician familiar with your individual condition.

Photo of author

Health Desk

Health Desk at Archyde.

Jermaine Wattimena Beats Luke Littler 10-8 to Reach Grand Slam of Darts Quarter-Finals